Significance of measurement of serum trough level and anti-drug antibody of adalimumab as personalised pharmacokinetics in patients with Crohn's disease: a subanalysis of the DIAMOND trial.

Aliment Pharmacol Ther · 2017 · PMC5656923 · PMID 28884856

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

25 Additionally, a recent report by Bond et al demonstrated that BMI did not differentially influence trough levels of adalimumab and IFX, but the investigators showed a trend towards a lower trough level in adalimumab‐treated patients with a BMI >30 kg/m 2 . 26 Thus, BMI seems to influence the response to adalimumab.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.